Press Releases
Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors
Montreal, Quebec--(Newsfile Corp. - June 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Lambert to its Board of Directors, effective immediately. Dr. Lambert brings more than four decades of scientific leadership and pioneering expertise in the development of antibody-drug conjugates ("ADCs"), further strengthening Defence's strategic capabilities as the Company advances its ACCUM-enabled ADC platform and partnership programs...
Share buybacks in Ericsson during the period May 25 - May 29, 2026
STOCKHOLM, June 1, 2026 /PRNewswire/ -- During the period May 25 - May 29, 2026, Telefonaktiebolaget LM Ericsson (publ) ("Ericsson") (LEI code 549300W9JLPW15XIFM52) repurchased own Class B shares (ISIN: SE0000108656) as follows: Date Aggregated daily volume (number of shares) Weighted average share price per day (SEK) Total daily transaction value (SEK) 25/05/2026 100,000 125.9244 12,592,440.00 26/05/2026 100,000 126.4263 12,642,630.00 27/05/2026 100,000 122.9061 12,290,610.00 28/05/2026 125,000 119.4022 14,925,275.00 29/05/2026 160,379 118.6136 19,023,130.55 Total 585,379 122.0988 71,474,085.55 The share repurchases are a part of the share buyback program of up to SEK 15,000,000,000 which Ericsson announced on April 16, 2026 and which runs between April 23, 2026 and March 31, 2027, at the latest. The Board of Directors intends to propose to the 2027 Annual General Meeting that the repurchased shares, other than those used to fulfil Ericsson's obligations under its share-related incentive programs, are cancelled...
Bayridge Resources Announces Non-Brokered Private Placement and Concurrent FT Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2026) - Bayridge Resources Corp. (CSE: BYRG) (OTCQB: BYRRF) (FSE: O0K0) ("Bayridge" or the "Company") is pleased to announce that it intends to complete a non-brokered private placement of up to 5,000,000 units ("Units") at a price of $0.20 per Unit for aggregate gross proceeds of up to $1,000,000 (the "Offering"). Each Unit it to be comprised of one common share and one-half of one common share purchase warrant (each whole warrant, a "Warrant"), with each Warrant exercisable for one additional common share (a "Warrant Share") at a price of $0.30 per Warrant Share for a period of 24 months from the date of issuance...
American Pacific Commences 15,000-Metre Program at the Madison Copper-Gold Project in Montana
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2026) - American Pacific Mining Corp. (CSE: USGD) (OTCQX: USGDF) (FSE: 1QC) (WKN: A422L8) is pleased to announce that it has commenced a 15,000-metre drill program combining both reverse circulation ("RC") and diamond core drilling at its Madison Copper-Gold Project ("Madison" or the "Project") in Montana. The drilling campaign will concentrate on shallow skarn mineralization for 10,000 metres and deeper porphyry mineralization for an additional 5,000 metres...
Nano One Announces Retirement of Founder and CEO Dan Blondal, President & Chief Strategy Officer Alex Holmes Appointed to CEO Role
Highlights Dan Blondal, Founder and Chief Executive Officer, to retire as of June 12, 2026, and will continue to support the Company in an advisory capacity Alex Holmes, President and Chief Strategy Officer, now appointed as Chief Executive Officer, effective June 12, 2026 Planned senior leadership succession reflects the Company's transition into its next phase of growth and commercialization VANCOUVER, BC / ACCESS Newswire / June 1, 2026 / Nano One Materials Corp. ("Nano One" or the "Company") (TSX:NANO)(OTCQB:NNOMF)(Frankfurt:LBMB), a process technology company specializing in lithium-ion battery cathode active materials, today announced that Dan Blondal, Founder and Chief Executive Officer, will retire from his executive management and Board Director role effective June 12, 2026. Alex Holmes, currently President and Chief Strategy Officer, will assume the role of Chief Executive Officer on the same date and join as a Director on the Board...
Edge Total Intelligence Reports Q1 2026 Revenue Growth of 121% Year-over-Year and 211% Sequentially and Rapidly Commercializes Acquired Austal Maritime and Aviation Defense Technology
High-Margin Software Revenue Scaling Alongside Department of War Shipbuilding Investment, AUKUS Maritime Demand, and Multi-Front Platform Expansion Revenue accelerating with high-margin profile - Q1 2026 revenue reached $1.69 million, up 121% year-over-year and 211% sequentially, with gross profit of approximately $1.11 million, reflecting the inherent scalability of edgeTI's software-based digital twin and decision intelligence platform. Austal acquisition closed and rapidly commercialized across the U.S. and Australia - edgeTI secured approximately $2.82 million in initial contract awards following the Austal asset acquisition, with the U.S. Navy award (via Austal USA) and two Australian awards supporting the Royal Australian Air Force and additional maritime acquisition program management, alongside key personnel onboarding and successful localization of acquired intellectual property...
Silvio Napoli Assumes Role as CEO of Lucid Following Completion of Leadership Transition
NEWARK, Calif., June 1, 2026 /PRNewswire/ -- Lucid Group, Inc. (NASDAQ: LCID), maker of the world's most advanced software-defined vehicles and technologies, today announced that Silvio Napoli has assumed the role of Chief Executive Officer (CEO), effective immediately.
Herbal Dispatch Reports First Quarter 2026 Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis e-commerce and distribution platform, today reported its financial results for the three months ended March 31, 2026 and provided an update on the Company's strategic initiatives and operational progress. Strategic Transition Underway During the first quarter of 2026, Herbal Dispatch continued positioning its business toward higher-value, more scalable growth opportunities...
Rokmaster Commences IP Survey at Mystery to Refine Porphyry Targets
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2026) - Rokmaster Resources Corp. (TSXV: RKR) (OTCQB: RKMSF) (FSE: 1RR1) ("Rokmaster" or "the Company") provides an update on exploration activities within the Nechako Project. Crews will soon mobilize to complete a detailed Induced Polarization Survey ("IP Survey") over several porphyry Cu-(Mo±Au) targets on the Mystery Property...
USA Rare Earth Expands Commitment to France with Plans for Additional Investment in the French Rare Earth Ecosystem
This planned investment would support the accelerated growth of the French separation, metal, alloy and magnet making ecosystem This planned investment would support the accelerated growth of the French separation, metal, alloy and magnet making ecosystem
Datavault AI Signs $2.0 Billion Structured Financing Term Sheet With Exclusive Global Tokenization Mandate
PHILADELPHIA--(BUSINESS WIRE)---- $DVLT #AIInfrastructure--Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset (“RWA”) tokenization technologies, today announced the execution on May 30, 2026 of a non-binding term sheet relating to a potential $2.0 billion dilutive structured financing transaction, pursuant to which the Company may issue shares at a purchase price of $1.55 to $2.00 per common share to an institutional i...
WORLDLINE : Finalisation of the divestment of MeTS perimeter - Press release
Worldline announces the finalisation of the divestment of the Mobility & e-Transactional Services perimeter to Magellan Partners Group
DMG Blockchain Solutions Inc. Announces 50-Megawatt AI Data Center Letter of Intent
VANCOUVER, British Columbia, June 01, 2026 (GLOBE NEWSWIRE) -- DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB: DMGGF) (FRANKFURT: 6AX) ("DMG" or the "Company"), a vertically integrated digital asset and data center technology company, announces it has signed a letter of intent (the “LOI”) to offer 50 megawatts critical IT load of artificial intelligence (AI) data center colocation services to a single tenant (“Tenant”) at its Christina Lake, British Columbia facility. The Tenant, who is under a non-disclosure agreement (“NDA") at this time, will be providing DMG with an investment grade backstop to review...
Recommendation from the nomination committee of Equinor ASA
The nomination committee of Equinor ASA (OSE:EQNR, NYSE:EQNR) recommends that the company's corporate assembly elects Jarle Roth as new chair of the board of directors of Equinor ASA.
Grande Portage Resources Advances Ongoing Project Studies and Fieldwork to Support New Amalga Gold Project Development
Preparing for the Federal Environmental Review (EIS) and Permitting Process VANCOUVER, BC / ACCESS Newswire / June 1, 2026 / Grande Portage Resources Ltd. (TSXV:GPG)(OTCQX:GPTRF)(FSE:GPB) ("Grande Portage" or the "Company") is pleased to provide a project update for the New Amalga Gold property near Juneau, Alaska...
Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026
Multiple confirmed partial and minor responses observed in patients with SGC Continuing very good safety profile, with removal of the lifetime maximum doxorubicin limit based on highly favorable cardiac safety LONDON and PHILADELPHIA, June 01, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform, today released updated Phase 1a/1b and pharmacokinetics (PK), safety, toxicity and preliminary efficacy data with faridoxorubicin (AVA6000, pre|CISION-enabled doxorubicin) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Christina Coughlin, CEO of Avacta, commented: "Today's data further underscores our confidence in both our Gen One product faridoxorubicin (AVA6000) and our pre|CISION technology to significantly improve treatment options for cancer patients...
DDN Advances Secure AI Factories with AI-Native Data Intelligence Infrastructure at NVIDIA GTC Taipei at COMPUTEX 2026
TAIPEI, Taiwan--(BUSINESS WIRE)-- #AI--DDN, the global leader in AI and data intelligence solutions, today announced new advancements to its AI data intelligence platform designed to help enterprises deploy agentic AI faster, strengthen governance and security, reduce operational complexity, and maximize GPU efficiency across enterprise-scale AI factories. The innovations deliver real-time observability, policy-based control, secure multi-tenant isolation, and AI-native data orchestration optimized f...
Endeavour Reports Fatal Accident at Lafigué Mine
ENDEAVOUR REPORTS FATAL ACCIDENT AT LAFIGUÉ MINE London, 1 June 2026 – Endeavour Mining plc (LSE:EDV, TSX:EDV, OTCQX:EDVMF) (“Endeavour” or the “Company”) regrets to report that a contractor colleague passed away on 29 May following a heavy mining equipment incident that occurred during water drainage activities, being carried out by a civil engineering contractor, at the Lafigué mine in Cote d'Ivoire. All relevant authorities have been informed, and Endeavour is conducting a comprehensive investigation into the incident to understand its root causes...
Orosur Mining Inc Announces Total Voting Rights
LONDON, UK / ACCESS Newswire / June 1, 2026 / Orosur Mining Inc. ("Orosur" or "the Company") (AIM:OMI)(TSXV:OMI), a minerals explorer and developer with projects in Colombia and Argentina, advises that during May 2026, the Company issued 2,850,000 new common shares of no par value each ("Common Shares") following the exercise of 2,850,000 restricted stock units (as announced on 19 May 2026) and 2,206,000 Common Shares for a total consideration of Cdn$551,500 following the exercise of 2,206,000 warrants at a price of Cdn$0.25 from its block listing announced on 14 January 2026. For the purposes of the Disclosure Guidance and Transparency Rules, the Company has 401,005,074 Common Shares in issue...
InterContinental Hotels Group PLC Announces Transaction in Own Shares - June 01
Purchase of own shares LONDON, UK / ACCESS Newswire / June 1, 2026 / The Company announces that on 29 May 2026 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 8 May 2025 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 17 February 2026, as announced on 17 February 2026...
Mkango Resources Limited Releases Q1 2026 Results
CALGARY, AB / ACCESS Newswire / June 1, 2026 / Mkango Resources Ltd (AIM:MKA)(TSX-V:MKA) (the "Company" or "Mkango"), is pleased to announce that it has released the Financial Statements and Management's Discussion and Analysis for the 3-month period ending 31 March 2026. The reports are available under the Company's profile on SEDARplus (www.sedarplus.com) and on the Company's website (https://mkango.ca/investors/financials/)...
VINFAST AND AUTOBRAINS LAUNCH FIRST AGENTIC AI L4 PROGRAM FOR SOUTHEAST ASIA WITH NVIDIA
Combining Autobrains' Agentic AI with NVIDIA DRIVE Hyperion Developing VinFast's level 4 to drive safely in real-world conditions Advancing autonomous driving without the premium cost that has stalled others TAIPEI, June 1, 2026 /PRNewswire/ -- VinFast (NASDAQ: VFS), and Autobrains announced at NVIDIA GTC Taipei at COMPUTEX 2026 today a strategic collaboration for a next-generation level 4 program for Southeast Asia built on NVIDIA DRIVE Hyperion. The collaboration marks a new step in VinFast's roadmap to make advanced autonomous driving technology more accessible at a reasonable cost, while opening a more practical approach to autonomous mobility solutions in the region's highly complex traffic environments...
Supermicro Introduces DCBBS Blueprints for NVIDIA Vera Rubin NVL72 and NVIDIA HGX™ Rubin NVL8, Built to Scale from 5MW to 1GW as an End-to-End Total Solution
End-to-End Blueprint Scalable from a 5MW to 1GW Power Envelope with full facility-side infrastructure for either single-tenant or multi-tenant deployments DLC-2 Direct Liquid Cooling: engineered for near total heat capture, power efficiency, and lower noise with full stack integration of cold plates, CDUs, manifolds, rear door heat exchangers, cooling towers, and SMC PG25-A ultra-high electrical impedance coolant Management Software Suite: End-to-end SuperCloud software delivers unified infrastructure control, deployment automation, developer tools, and multi-tenant GPU cloud management In-Rack, In-Row, and Site Infrastructure Solutions covering every deployment layer from rack integration to in-row CDUs and SuperCluster configurations, to site-level infrastructure Dedicated Team of Supermicro Experts manage the complete deployment lifecycle: site survey, project design, integration, deployment, and ongoing support Supporting NVIDIA's latest reference architecture integrating NVIDIA Context Memory Storage Platform, NVIDIA Spectrum™-X Ethernet, and NVIDIA Quantum-X800 InfiniBand Platform SAN JOSE, Calif. and TAIPEI, Taiwan, June 1, 2026 /PRNewswire/ -- Super Micro Computer, Inc. (NASDAQ: SMCI), a Total IT Solutions provider for AI, Cloud, Storage, and 5G/Edge, introduces Data Center Building Block Solutions (DCBBS) Blueprints based on the NVIDIA Vera Rubin NVL72 and the NVIDIA HGX Rubin NVL8 platforms...
Autobrains and Uber to Launch Agentic AI Robotaxi Program in Munich built on NVIDIA DRIVE Hyperion
TAIPEI, Taiwan--(BUSINESS WIRE)--Uber (NYSE: UBER), and Autobrains announced at GTC Taipei today a strategic collaboration to launch a robotaxi program in Munich, combining Uber's ride-hailing platform, Autobrains' agentic autonomous driving intelligence, and NVIDIA DRIVE robotaxi-ready level 4 Hyperion platform to support scalable autonomous mobility for commercial ride-hailing. Pending regulatory approval, Munich will serve as the first deployment city for the robotaxi program, establishing a...
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
BRUSSELS, Belgium and CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced that The Lancet, a world-leading medical journal, has published the full results from the Phase 3 PHOENYCS GO clinical trial evaluating dapirolizumab pegol (DZP), an investigational, novel Fc-free CD40L inhibitor, in patients living with moderate-to-severe active systemic lupus erythematosus (SLE). The results showed statistically significant improvement in disease activity with DZP added to standard of care (SOC) versus placebo plus standard of care.1
Cadence Unveils Industry's First Fully Autonomous Virtual Engineer for Chip Design, powered by NVIDIA
SAN JOSE, Calif.--(BUSINESS WIRE)--At Computex 2026, Cadence (Nasdaq: CDNS) announced the industry's first fully autonomous virtual agentic AI design engineer, extending the ChipStack™ AI Super Agent to Level-5 autonomy. Built on Cadence's AI-driven electronic design automation (EDA) portfolio with NVIDIA Nemotron models, and secured by NVIDIA OpenShell runtime, the new agentic capabilities enable customers to run dynamic simulations in automated workflows. At NVIDIA, 1000s of engineers are usi...
Synera Advances AI Agents for Design and Engineering Simulation with NVIDIA
BREMEN, Germany--(BUSINESS WIRE)--Synera's collaboration with NVIDIA highlights the growing role of agentic AI in transforming physical product development.
Nutanix Unified Storage Achieves NVIDIA Certification as Enterprises Race to Build AI Factories
Nutanix Unified Storage validated at enterprise level to support NVIDIA-powered AI infrastructure for production workloads Nutanix advances AI-native storage with planned NVIDIA BlueField-4 STX support SAN JOSE, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Nutanix (NASDAQ: NTNX), a leader in hybrid multicloud computing, today announced the Nutanix Unified Storage (NUS) solution is NVIDIA-Certified at the enterprise level...
MinIO AIStor and MemKV Deliver the Secure AI Data Path with NVIDIA Vera BlueField-4 STX
The only object storage and context memory solution purpose-built across the complete AI data pipeline, from persistent S3 storage to in-context GPU memory The only object storage and context memory solution purpose-built across the complete AI data pipeline, from persistent S3 storage to in-context GPU memory
HP Debuts PCs Built for the Next Wave of Windows PC Experiences Powered by NVIDIA RTX Spark™
Unified portfolio delivers pre‑configured tools and secure local processing to accelerate AI workflows for creators, developers, and gamers Unified portfolio delivers pre‑configured tools and secure local processing to accelerate AI workflows for creators, developers, and gamers
HPE Introduces CPU Server with NVIDIA Vera CPU, Purpose-built for Agentic AI
HOUSTON & TAIPEI, Taiwan--(BUSINESS WIRE)--COMPUTEX – HPE (NYSE: HPE) today announced the expansion of its industry-leading server portfolio with the introduction of the HPE ProLiant Compute DL394 Gen12, powered by NVIDIA Vera CPU. This next-generation server is engineered specifically to address the compute demands of emerging high-performance AI and data processing workloads delivering industry-leading agentic AI CPU performance, memory bandwidth, and low latency. Built on a foundation of adv...
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
Basel, June 1, 2026 – Novartis will present new data from 31 abstracts across its industry-leading immunology portfolio at the European Alliance of Associations for Rheumatology (EULAR) Congress on June 3-6 in London, advancing scientific insight into high-burden autoimmune diseases.
Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology
Allschwil, Switzerland – June 1, 2026 Idorsia Ltd (SIX: IDIA) today announced additional positive clinical results for IDOR-1134-2831, its vaccine targeting Clostridioides difficile (C. difficile) in a Phase 1 clinical pharmacology trial. The glycan target of this vaccine is present on both bacteria and spores – the transmissible form of the pathogen responsible for spreading infection – of the most clinically relevant C. difficile strains, including hypervirulent variants. Following initial results in June 2025, which provided the first clinical validation for Idorsia's synthetic glycan vaccine technology, the company advanced the program with a higher-dose cohort...
NVIDIA and TSMC Bring AI Into Fabs to Advance Semiconductor Design and Manufacturing
News Summary: NVIDIA CUDA-X libraries and AI models are accelerating TSMC workloads across lithography, transistor and process simulation, advanced process control and fab operations optimization. TSMC is using NVIDIA Metropolis and NVIDIA TAO Toolkit to advance automated defect inspection with vision AI, improving detection of nanometer-scale defects while reducing repeated labeling and retraining...
Roche to present new data advancing its obesity portfolio at the American Diabetes Association's 2026 Scientific Sessions
Basel, 1 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that new data from its obesity portfolio will be presented at the 2026 Scientific Sessions of the American Diabetes Association (ADA). The insights demonstrate significant progress in addressing a range of unmet needs for people living with obesity or overweight such as long-term treatment adherence, which could be supported by a favorable safety and tolerability profile...
Blaize and Winmate Bring Rugged Edge AI from the U.S. to the Global Stage at COMPUTEX 2026, Advancing Joint Mission-Critical and Industrial Solutions
Following their U.S. debut at MDEX in Detroit, the companies are showcasing integrated rugged edge AI concepts at COMPUTEX 2026 and discussing potential future collaboration opportunities in aerial and embedded AI systems. TAIPEI and EL DORADO HILLS, Calif.
New analysis of Idorsia's aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension
Allschwil, Switzerland – June 01, 2026 Idorsia Ltd (SIX: IDIA) announces new analyses from the Phase 3 PRECISION study demonstrating that aprocitentan, Idorsia's dual endothelin receptor antagonist, significantly reduces albuminuria and improves albuminuria risk categories in patients with resistant hypertension. The data were presented by Prof. Markus Schlaich at the 35th Congress of the European Society of Hypertension (ESH)...
Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association's 2026 Scientific Sessions
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that new data from its obesity portfolio will be presented at the 2026 Scientific Sessions of the American Diabetes Association (ADA). The insights demonstrate significant progress in addressing a range of unmet needs for people living with obesity or overweight such as long-term treatment adherence, which could be supported by a favorable safety and tolerability p...
BNP PARIBAS PRESENTS THE GROWTH STRATEGY OF ITS COMMERCIAL BANK IN BELGIUM (CPBB) AND RAISES ITS PROFITABILITY TARGETS TO 22% PRE-TAX RONE IN 2028 AND 25% IN 2030
BNP PARIBAS PRESENTS THE GROWTH STRATEGY OF ITS COMMERCIAL BANK IN BELGIUM (CPBB) AND RAISES ITS PROFITABILITY TARGETS TO 22% PRE-TAX RONE IN 2028 AND 25% IN 2030
NVIDIA, Foxconn and Taiwan Medical Centers Bring Agentic and Physical AI to ‘Healthy Taiwan'
News Summary: Foxconn is deploying NVIDIA AI across Taiwan's leading medical centers, transitioning from using individual AI tools to coordinated AI agent workforces that help clinicians reason, document and orchestrate care. Foxconn's CoDoctor AI platform with new AI agents and Nurabot nursing collaborative robots — now powered by NVIDIA NemoClaw — have moved from pilot programs into clinical operations...
NVIDIA Releases Major Collection of Open Source Agent Tools and Skills for Physical AI
News Summary: NVIDIA releases a major open source collection of physical AI agent skills and tools spanning NVIDIA Omniverse, Cosmos, Alpamayo and Metropolis for robotics, autonomous vehicles, vision AI and industrial digital twins. New physical AI skills turn complex physical AI training, evaluation and deployment workflows into repeatable, optimized and agent-executable instructions...
NVIDIA Announces NVIDIA Isaac GR00T Reference Humanoid Robot for Academic Research
News Summary: NVIDIA announces an open humanoid robot reference design built on the NVIDIA Isaac GR00T platform, combining a Unitree H2 Plus humanoid robot, Sharpa five-fingered hands for dexterous manipulation, NVIDIA Jetson Thor onboard compute for advanced reasoning and control, and NVIDIA Isaac GR00T open software and models. The Isaac GR00T development platform — spanning data capture and generation to robot model evaluation and deployment — helps researchers and developers accelerate humanoid development workflows...
NVIDIA DRIVE Hyperion Becomes the Global Platform for a Robotaxi-Ready World
News Summary: Foxconn is expanding its strategic collaboration with NVIDIA to develop and deploy level 4-ready robotaxi fleets in Taiwan, beginning in Kaohsiung, with plans to scale across Asia. VinFast is working with Autobrains to bring level 4 vehicles built on DRIVE Hyperion to the Southeast Asia market...
XPENG Announces Vehicle Delivery Results for May 2026
GUANGZHOU, China, June 1, 2026 /PRNewswire/ -- XPeng Inc. ("XPENG" or the "Company," NYSE: XPEV and HKEX: 9868), a leading global AI mobility technology company, today announced its vehicle delivery results for May 2026. XPENG delivered a total of 32,158 vehicles in May, representing a 4% increase from the prior month...
NVIDIA Launches Alpamayo 2 Super Open Reasoning Model for Robotaxis
News Summary: NVIDIA's most powerful open reasoning model to date, NVIDIA Alpamayo 2 Super is an open 32-billion-parameter reasoning VLA model that reasons, plans and acts across the full driving stack for safer, scalable level 4 development. NVIDIA AlpaGym is a new high-throughput, closed-loop reinforcement learning framework that trains AV models on the consequences of their driving decisions in simulation before road deployment...
NVIDIA Launches Cosmos 3, the Open Frontier Foundation Model for Physical AI
News Summary: NVIDIA Cosmos 3 is a new leaderboard-topping open physical AI foundation model, built on a breakthrough mixture-of-transformers architecture for physical AI reasoning, world simulation and action generation. Cosmos 3 is the world's first fully open omnimodel with native vision reasoning and multimodal generation across text, image, video, ambient sound and action for state-of-the-art synthetic data generation and physical AI policy model development...
NVIDIA DGX Station for Windows Puts a Trillion-Parameter AI Supercomputer on Every Enterprise Desk
News Summary: NVIDIA announces DGX Station for Windows — the world's most powerful deskside AI supercomputer for developing and running agents on Windows — built on the NVIDIA GB300 Grace Blackwell Ultra Desktop Superchip, coming in Q4 this year. DGX Station brings frontier AI agents to Windows — enabling enterprise developers, researchers, engineers, designers and data scientists to build and deploy AI across the workflows and applications their business runs on...
NVIDIA and Microsoft Reinvent Windows PCs for the Age of Personal AI
RTX Spark — a 1-Petaflop Superchip, the Full CUDA and RTX Ecosystem, and Windows-Native Agents — a New Beginning for Personal Computers RTX Spark — a 1-Petaflop Superchip, the Full CUDA and RTX Ecosystem, and Windows-Native Agents — a New Beginning for Personal Computers
Enterprise Software Leaders Build AI Agents With NVIDIA
News Summary: New NVIDIA Agent Toolkit software — including latest NVIDIA NemoClaw blueprints, Nemotron models, OpenShell secure runtime and CUDA-X libraries with agent skills — delivers open source foundations for enterprise development. Cadence, Dassault Systèmes, Siemens and Synopsys are among the first to use NVIDIA NemoClaw to build autonomous AI engineers working as digital coworkers to execute simulation and verification workflows — compressing weeks of engineering work into hours...
HONEYWELL UNVEILS NEW BRANDS EFFECTIVE POST SPIN-OFF: HONEYWELL TECHNOLOGIES AND HONEYWELL AEROSPACE
CHARLOTTE, N.C., June 1, 2026 /PRNewswire/ -- Honeywell (NASDAQ: HON) today announced the new brand identities for its automation and aerospace businesses ─ Honeywell Technologies and Honeywell Aerospace.
IREN and BE Networks Accelerate Deployment of Large-Scale AI Factory with NVIDIA DSX Air
High fidelity simulation environment will help validate large NVIDIA GPU AI infrastructure before physical deployment NEW YORK, June 1, 2026 /PRNewswire/ -- BE Networks, a leading provider of networking and observability software solutions for AI datacenters today announced that it is working with IREN Limited (NASDAQ: IREN), a leading next-generation data center and AI cloud infrastructure company, to leverage NVIDIA DSX Air to simulate and validate the network architecture supporting IREN's upcoming deployment of more than 50,000 NVIDIA Blackwell Ultra GPUs . The initiative will enable IREN and BE Networks to utilize a production-representative digital twin of IREN's AI cloud environment before the physical infrastructure is deployed...
NIO Inc. Provides May 2026 Delivery Update
SHANGHAI, June 01, 2026 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced its May 2026 delivery results.
Kelyniam Global to Present at Planet MicroCap Las Vegas 2026 - From Single Product to Regenerative Medicine Leader
COLLINSVILLE, Conn., June 1, 2026 /PRNewswire/ -- Kelyniam Global, Inc. (OTC: KLYG), a leader in patient-specific cranial and craniofacial implants, today announced it will present at the Planet MicroCap Las Vegas 2026 conference on Wednesday, June 17, 2026 at 4:30 PM PST at the Bellagio Resort & Hotel...
Power Integrations Unveils Space-Saving, Ultra-Slim Auxiliary PSU Reference Designs for NVIDIA Kyber 800 VDC AI Data Center
TAIPEI, Taiwan--(BUSINESS WIRE)---- $POWI--COMPUTEX – Power Integrations (NASDAQ: POWI), the leader in high-voltage integrated circuits for energy-efficient power conversion, today introduced two new ultra-slim, compact auxiliary power supply reference designs for 800 VDC AI data centers. The single-output, 15 W design is only 30 mm by 30 mm with a 7 mm profile, while the isolated, six-rail, 35 W design is only 80 mm by 60 mm with an 8 mm profile. Optimized specifically for the NVIDIA Kyber liquid-cooled...
NVIDIA Unveils Vera, the CPU for Agents
1.8x Faster Than x86 Processors to Drive Diverse Workloads Across Industries, Generating More Data Center Token Revenue 1.8x Faster Than x86 Processors to Drive Diverse Workloads Across Industries, Generating More Data Center Token Revenue
NVIDIA Vera BlueField-4 STX Brings Agentic AI Storage Processing With In-Silicon Security
New and Enhanced NVIDIA DOCA Security Capabilities for Vera BlueField-4 STX Help Protect AI Agents, Context Memory and File-Based Data Access Directly in Silicon New and Enhanced NVIDIA DOCA Security Capabilities for Vera BlueField-4 STX Help Protect AI Agents, Context Memory and File-Based Data Access Directly in Silicon
NVIDIA Vera Rubin Ramps Into Full Production to Power Agentic AI Factories Worldwide
News Summary: NVIDIA Vera Rubin is ramping into full production, with Taiwan's top server makers and global supply chain leaders manufacturing Vera Rubin-based systems at scale — fueling AI labs, cloud providers and hyperscalers to build tomorrow's intelligence. Vera Rubin delivers the POD-scale foundation for next-generation AI factories — with 10x agent throughput at scale compared with the previous-generation NVIDIA Grace Blackwell platform...
NVIDIA DSX Gives Infrastructure Builders the Playbook for AI Factories
News Summary: Engineered from the ground up for AI factories, the NVIDIA DSX platform defines how next-generation infrastructure is designed, built and operated — driving lowest token cost and accelerating time to first production across NVIDIA chips, systems, software, facilities and partner technologies. New DSX MaxLPS software enables AI infrastructure and factories to deliver the lowest token cost by maximizing token performance per megawatt...
Supermicro Launches New Server Solutions with Intel Xeon 6+ Processors to Reduce TCO and Accelerate Time-to-Online for Large-Scale Cloud and Data Centers
12 new systems across Hyper, SuperBlade , FlexTwin™, and GrandTwin families offer industry-leading core density with up to 576 efficiency cores per server Breakthrough performance-per-watt and energy efficiency designed to lower TCO and reduce power consumption in high-density cloud and enterprise environments Optimized for cloud-native, virtualization, 5G analytics, content delivery, and throughput-intensive workloads SAN JOSE, Calif. and TAIPEI, May 31, 2026 /PRNewswire/ -- Super Micro Computer, Inc (NASDAQ: SMCI), an AI, Enterprise, Storage, 5G/Edge total solution provider featuring Data Center Building Block Solutions (DCBBS), today announced the launch of 12 new server platforms optimized for new Intel Xeon 6+ processors...
Topicus.com Inc. Announces a Revised Proposal to Acquire ReadyTech
TORONTO, May 31, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV: TOI), acting through its subsidiary TSS Europe B.V. (“TSS”), today submitted a revised non-binding indicative proposal to acquire ReadyTech Holdings Limited (ASX: RDY) (“ReadyTech”) by way of a scheme of arrangement for cash consideration of $2.00 per share (the “Scheme Consideration”), or in the alternative, an off-market takeover bid with a 50.1% minimum acceptance condition at a cash consideration of $1.75 per share (the "Takeover Consideration") (together, the "Revised Proposal")1. All references herein to currency are in Australian dollars...
LG Display to showcase world's largest Gaming OLED lineup in Taiwan
SEOUL, South Korea, May 31, 2026 /PRNewswire/ -- LG Display, the world's leading innovator of display technologies, announced today that it will unveil its latest Gaming OLED products at a Taipei roadshow event from June 4 to 10. The company is accelerating its expansion in the fast-growing OLED gaming monitor market by showcasing world-first and best-in-class technologies alongside the industry's most comprehensive lineup...
Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term analysis results of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against Claudin18.2), as sequential therapy after first-line (1L) treatment in patients with advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA), have been presented as a poster presentation at the 2026 ASCO Annual Meeting on May 30, 2026, 13:30 – 16:30, CDT. The poster was titled "Long-term Follow-up of Satricabtagene autoleucel (satri-cel) as Sequential Therapy After First-Line Treatment for Advanced Gastric Cancer – a subgroup analysis" [1]...
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved an objective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benefit across squamous (ORR: 87.5%) and non‑squamous (ORR: 75.0%) histologies. In the PD-L1-negative/low population (TPS ≤5%) squamous NSCLC cohort, CS2009 in combination with chemotherapy achieved an ORR of 75.0% and a DCR of 100.0%; notably, PD-L1-negative patients within this cohort achieved an ORR of 100.0%; the current efficacy readout remains immature due to the short follow‑up for most patients in this cohort...
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression . The 3→ 1.5 mg/kg dose group (n=22) showed ORR of 86.4% , confirmed ORR (cORR) of 81.8% (95% CI: 59.7-94.8) and DCR of 100% The second stage of the PoC study is ongoing in head-to-head comparison vs...
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC IBI363 has entered a global Phase 3 clinical study (MarsLight-11) for IO-resistant squamous NSCLC; pending regulatory communications, initiation of a global Phase 3 clinical study of IBI363 for IO-resistant non-squamous NSCLC is also planned. Innovent and Takeda are co-developing IBI363 (Takeda R&D code: TAK-928) globally...
BriaCell Therapeutics Announces Pricing of Offering
PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent's fees and other offering expenses, are expected to be approximately $4.7 million. The offering is expected to close on June 2, 2026, subject to satisfaction of customary closing conditions. The Company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq...
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced that the Company presented its first dataset of alrizomadlin (APG-115), an MDM2-p53 inhibitor from the Company's apoptosis-targeted pipeline, as monotherapy or in combination with lisaftoclax (APG-2575) in pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs), in a rapid oral presentation at the 62nd American Society of Clinical Oncology (ASCO) Annual Meeting...
Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting...
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced results from a Phase Ib study evaluating olverembatinib (HQP1351), the company's core product, in combination with bispecific T-cell engager antibody (immunotherapy) blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting...
Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Total Sales and Shipments of EAI Robots Reached 69 Units in May, a New Record, Exceeding the Combined Total for the Months of March and April
LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today shared a weekly business update from YT Jia, Founder and Global CEO of FF. “Welcome to Issue 57 of our weekly report. In the final week of May, we would like to highlight two pieces of good news: first, total sales and shipments of EAI robots reached 69 units in May, exceeding the combined total for...
Atlas Salt Announces $10 Million Bought Deal LIFE Financing
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Cango Inc. Reports First Quarter 2026 Unaudited Financial Results
DALLAS, May 31, 2026 /PRNewswire/ -- Cango Inc. (NYSE: CANG) ("Cango" or the "Company"), a leading Bitcoin miner leveraging its global operations to develop an integrated energy and AI compute platform, today announced its unaudited financial results for the first quarter ended March 31, 2026. First Quarter of 2026 Financial and Operational Highlights Financial Performance: In the first quarter of 2026, the Company generated total revenue of US$102.0 million, primarily driven by US$98.4 million from its Bitcoin mining business...
As Global Markets Reach New Highs, Growing Numbers of Microcap and Penny Stock Investors Worldwide Are Discovering ELEKTROS Inc.-A Unique Opportunity at an Early-Stage Valuation as Momentum Continues Building Across the Investment Community
ELEKTROS Inc. - Publicly Traded (Ticker Symbol:ELEK) WEST PALM BEACH, FL / ACCESS Newswire / May 31, 2026 / As U.S. financial markets continue rallying and investor optimism expands throughout the global investment landscape, management believes renewed enthusiasm surrounding emerging growth companies and microcap opportunities continues accelerating across worldwide markets. Management further stated that increasing investor attention toward lithium supply chains, EV infrastructure, and next-generation charging technologies continues strengthening as more investors globally continue discovering the long-term vision and growth potential of ELEKTROS Inc. Reuters recently reported that expanding high-speed charging infrastructure remains one of the most important components necessary for accelerating electric vehicle adoption worldwide, as governments and major corporations continue investing billions into EV charging expansion initiatives...
Berkshire Hathaway to Acquire Taylor Morrison Home Corporation for $8.5 Billion
All-cash transaction delivers significant and certain value for Taylor Morrison shareholders; purchase price represents approximately 24% premium to latest closing stock price Transaction provides attractive opportunity for Taylor Morrison team members and partners to execute continued growth trajectory with the strength of Berkshire Hathaway SCOTTSDALE, Ariz. and OMAHA, Neb...
As Global Markets Surge to New Highs, Investors Worldwide Are Discovering ELEKTROS Inc. - A Rare Opportunity in Lithium Mining, Rare Earth Minerals and Advanced EV Patent Technology as Growing Momentum Continues Capturing the Attention of Microcap and Penny Stock Investors Across the Globe
ELEKTROS Inc. - Publicly Traded (Ticker Symbol:ELEK) WEST PALM BEACH, FL / ACCESS Newswire / May 31, 2026 / As U.S. financial markets continue rallying and investor optimism expands throughout the global investment landscape, management believes renewed enthusiasm surrounding emerging growth companies and microcap opportunities continues accelerating across worldwide markets. Management further stated that increasing investor attention toward lithium supply chains, EV infrastructure, and next-generation charging technologies continues strengthening as more investors globally continue discovering the long-term vision and growth potential of ELEKTROS Inc. Reuters recently reported that expanding high-speed charging infrastructure remains one of the most important components necessary for accelerating electric vehicle adoption worldwide, as governments and major corporations continue investing billions into EV charging expansion initiatives...
As Global Markets Discover Elektros, Microcap and Penny Stock Investors Are Beginning To Take Notice of a Growing EV Patent Technology and Lithium Mining Company
WEST PALM BEACH, FL / ACCESS Newswire / May 31, 2026 / Elektros Inc. (OTC PINK:ELEK) is pleased to provide shareholders with an update regarding the Company's intellectual property initiatives surrounding U.S. Patent No. 12,522,100, entitled "Multi-Port Charging Assembly for Electric Vehicles.
Diana Shipping Inc. Sends Letter to Genco Shipping & Trading Shareholders Making the Case for Electing Six Independent Nominees With Proven Track Records of Creating Shareholder Value
Details Why the Entrenched Genco Board Should Not Be Trusted to Act in Shareholders' Best Interests Contrasts Diana's Six Accomplished, Independent Nominees Against a Board That Has Spent Six Months and Over $13 Million Protecting Itself and Management Releases Video Message to Genco Shareholders from CEO Semiramis Paliou Outlining the Compelling Value of Diana's Offer and the Urgent Need for Board Change Calls on Genco Shareholders to Elect a Board That Will Finally Put Shareholders First by Voting the GOLD Universal Proxy Card "FOR" Diana's Six Independent Director Nominees ATHENS, Greece, May 31, 2026 (GLOBE NEWSWIRE) -- Diana Shipping Inc. (NYSE: DSX) (“Diana” or “the Company”), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels that is the largest shareholder of Genco Shipping & Trading Limited (NYSE: GNK) (“Genco”), today sent an open letter to Genco shareholders making the definitive case for electing Diana's six independent director nominees to the Genco Board of Directors (the “Genco Board”) — Gustave Brun-Lie, Paul Cornell, Chao Sih Hing Francois, Jens Ismar, Viktoria Poziopoulou and Quentin Soanes — at Genco's 2026 Annual Meeting of Shareholders to be held on June 18, 2026. In today's letter, Diana draws a sharp contrast between its six independent nominees — accomplished shipping, finance, M&A and legal executives with proven track records of creating and maximizing shareholder value — and the entrenched Genco Board, which has consistently prioritized management's compensation and control over the interests of the shareholders it is supposed to represent...
UGRO: urban-gro, Inc. (Nasdaq: UGRO) Announces Lanka Premier League Season 6 Player Auction Set for June 1, 2026 @ 5:00 AM EDT (2:30 PM Colombo Time)
Worldwide Fans Invited to Follow Live at https://lpl.flashsportsandmedia.com
iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo
BEIJING, May 31, 2026 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced that it has entered into certain asset transfer agreements to acquire the businesses and assets related to two products, All Knowledge (全知识) and Perfect Lingo (万词王) (the "Acquisitions"), for an aggregate consideration of RMB94.0 million, subject to potential two-way price adjustments and contingent earn-out payments. All Knowledge is an app that focuses on humanities and AI literacy, providing users with AI-powered interactive access to knowledge across history, culture, literature, philosophy, art, and other humanities fields...
GRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF SHAREHOLDERS OF ZOETIS, INC. (ZTS)
Philadelphia, Pennsylvania--(Newsfile Corp. - May 31, 2026) - WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Zoetis, Inc. (NYSE: ZTS).
CPKC to maintain rail operations across Canada during IBEW strike
CALGARY, AB, May 31, 2026 /PRNewswire/ - Canadian Pacific Kansas City (TSX: CP) (NYSE: CP) (CPKC) today said it has implemented contingency plans to maintain railway operations across Canada following the International Brotherhood of Electrical Worker (IBEW) Canadian Signals and Communications System Council No. 11's rejection of CPKC's latest contract offers...
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and sponsored by Summit's partner Akeso, Inc. (HKEX Code: 9926.HK), will be presented today as part of the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation is entitled “Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untrea...
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
Houston, Texas and Tuebingen , Germany, May 31, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced the presentation of extended data from the ongoing Phase 1 clinical trial evaluating its TCR bispecific (TCER) candidate IMA401 targeting MAGEA4/8 in heavily pretreated patients with solid tumors, including head and neck cancer and lung cancer, in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL, USA. The data show a consistent and favorable tolerability profile across multiple tumor types and encouraging anti-tumor activity at the recommended Phase 2 dose (RP2D) with or without the immune checkpoint inhibitor (ICI) pembrolizumab. Results from the Phase 1 study are being published simultaneously in Nature Medicine ...
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm
Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the risk of developing metastasis or death 1
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the next-generation of Lens, its pioneering agentic AI platform designed to accelerate drug development and research. This evolution seamlessly connects Tempus' multimodal data, AI tooling and computational infrastructure to deliver actionable insights at the pace required for drug development. The next-generation of the Lens platf...
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
More than one-third of responders with previously treated disease achieved complete responses, with median duration of response not yet reached, as reported in new Journal of Clinical Oncology publication RYBREVANT FASPRO™, an EGFR- and MET-targeting dual inhibitor, is the first and only subcutaneous therapy being evaluated in this setting Johnson & Johnson submitted a supplemental Biologics License Application to U.S. FDA seeking approval for this indication CHICAGO, May 31, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced pivotal results from the Phase 1b/2 OrigAMI-4 study showing that subcutaneous amivantamab and hyaluronidase-lpuj delivered durable responses in patients with advanced head and neck squamous cell carcinoma previously treated with immunotherapy and chemotherapy. Confirmed overall response rate was 42 percent, with more than one-third of responders achieving complete responses...
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis or death Data selected to open the plenary presentation at ASCO 2026 and published in The New England Journal of Medicine CHICAGO, May 31, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation therapy, ADT), given for six months before and after prostate cancer surgery, significantly improved key short- and long-term clinical outcomes for patients with high-risk localized or locally advanced disease. The trial met both primary endpoints...
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
Results simultaneously published in The New England Journal of Medicine Results simultaneously published in The New England Journal of Medicine
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
Phase 3 LIBRETTO-432 results establish RET fusions alongside EGFR mutations and ALK fusions as biomarkers in early-stage lung cancer that are associated with dramatic treatment outcomes, underscoring the importance of comprehensive biomarker testing across all stages of disease These data will be published in the New England Journal of Medicine and simultaneously presented during the Plenary Session at the 2026 ASCO Annual Meeting INDIANAPOLIS, May 31, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo in patients with early-stage (IB-IIIA) rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in investigator-assessed event-free survival (EFS) with selpercatinib reducing the risk of disease recurrence or death by 83% versus placebo in the primary analysis population...
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease control rate of 52% in heavily pretreated HLA-A*02:01-positive patients with melanoma Data support selection of 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma Clinical benefit was consistent across difficult-to-treat subgroups, including patients with primary PD-1 resistance Brenetafusp was generally well tolerated as monotherapy and in combination with pembrolizumab (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md...
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for RP2 alone and in combination with nivolumab in patients with advanced solid tumors during an oral session at the 2026 American Society of Clinical Oncology annual meeting...
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating BRAFTOVI (encorafenib) in combination with cetuximab (marketed as ERBITUX) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) versus FOLFIRI with or without bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. These results will be...
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
The Galleri Multi-Cancer Early Detection (MCED) Test Increased Cancer Detection 6.5 Fold When Added to Recommended Screenings for Breast, Colorectal, Cervical and Lung Cancer 71% of the New Cancers Detected by the Galleri Test Were in Stages I-III MENLO PARK, Calif., May 31, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that positive performance and safety results from the analysis of the full 35,878 cohort of its registrational PATHFINDER 2 study are being presented during an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting[1]...
SMX and the Age of Parity: Certified Recycling Becomes the New Economics of Plastic
NEW YORK CITY, NY / ACCESS Newswire / May 31, 2026 / Plastic has always been treated as one of the world's most dependable materials: inexpensive, scalable, lightweight, and available in enormous volumes. It protects food, moves medicine, reduces shipping weight, supports health care, enables packaging, and keeps everyday products affordable...